Роль высокодозной химиотерапии с трансплантацией клеток-предшественников гемопоэза в лечении множественной миеломы

С. В. Миненко, А Ю Попов, Nikolay V. Zhukov et al. · Oncohematology · 2008

Treatment results in a group of patients with multiple myeloma (n =18) treated with melfalan (200 mg/m2) followed by autologous peripheral blood stem cell transplantation as a second-line therapy are presented. Thirteen patients received one course of high-dose chemotherapy (HDCT), 5 had 2 courses. Before HDCT all treated patients achieved a partial remission (15 patients after 3 courses VAD, 3 patients after 3 courses of VAD and 2 courses of velcade-doxorubicinprednisolone). The median time to disease progression was 33.1 (range 26-40) months; that of overall survival was 55.4 (range 2940) months.

Cited by 0 works.

Authors